Taishan Hu is a highly experienced professional with a strong background in biochemistry, cellular & molecular biology, and immunology.

He has specialized expertise in various areas including monoclonal antibody generation, FACS analysis, cell-based assays, and genome editing technologies like CRISPR.

As a project leader, Taishan has played key roles in downstream process development for rhIL-3 and pre-clinical drug development for cancer immunotherapy focusing on CAR T/CIK therapies.

He has successfully led independent research initiatives on T and NKT cells, resulting in significant discoveries and securing grants from reputable organizations like AHA and NIH.

Taishan Hu holds a Ph.D. in Pharmacology from the Shanghai Institute of Materia Medica, Academia Sinica, and has a rich professional history working in various prestigious institutions including Children's Hospital of Philadelphia, Rockland Immunochemicals Inc., Fox Chase Cancer Center, and many others.